Why an Independent COA Matters: Purity Discrepancies, Endotoxin and Impurity Immunogenicity

A Certificate of Analysis (COA) is only useful if it reflects the specific lot in hand and reports the right attributes with disclosed methods. Recent reporting and the peer-reviewed literature converge on a single message: a stated purity percentage, taken alone, is an incomplete description of a synthetic peptide. This article reviews three analytical dimensions — purity measurement, bacterial endotoxin and impurity immunogenicity — strictly as quality-characterization topics.

Independent testing services that re-analyze samples against the supplier COA have reported frequent discrepancies between stated and measured purity. One commercial testing laboratory has reported that a large majority of submitted samples showed measurable deviations from the supplier figure, with overstated purity the most common pattern. These figures are directionally informative but should be read with their source in mind.

The widely cited claim that roughly three-quarters of samples deviate from the COA originates from a commercial testing laboratory own aggregated dataset, not a peer-reviewed study with published methodology. It should be presented as an attributed, directional indicator — not a precise, independently validated rate. The credible takeaway is qualitative and well supported across sources: supplier purity claims and independently measured purity frequently disagree, so the claim is not self-verifying.

There is a methodological reason two honest laboratories can report different purity for the same vial. Reversed-phase HPLC with UV detection quantifies peak area, but impurities do not necessarily absorb UV light identically to the main peptide. Without applying relative response factor (RRF) corrections, area-percent purity can systematically misstate the true impurity content. The peer-reviewed analytical literature has argued explicitly for RRF implementation in peptide impurity assessment. Practically: a purity figure is only interpretable alongside the method, the detection wavelength and whether response factors were applied.

Chromatographic purity describes the proportion of peptide-related species. It does not measure bacterial endotoxin — lipopolysaccharide fragments from Gram-negative bacteria — which is a separate analyte requiring a separate assay. A sample can report a high purity percentage and still carry a meaningful endotoxin burden, because the two measurements answer different questions. Independent community testing circulated during the current window has repeatedly highlighted endotoxin as an attribute absent from many supplier certificates.

The bacterial endotoxins test is standardized in USP General Chapter 85, typically performed with a Limulus Amebocyte Lysate (LAL) assay and reported in endotoxin units. A complete characterization for a parenteral-grade synthetic peptide therefore includes an endotoxin result against a defined limit, not purity alone. Its absence from a certificate is itself informative: it means the attribute was not documented for that lot.

A December 2025 analysis in Frontiers in Immunology, with FDA-affiliated authors, examined peptide-related impurities in a generic teriparatide context and reported that synthesis impurities disrupting a tolerogenic region of the sequence carried elevated immunogenic potential relative to the reference product. The broader principle is the relevant one for verification: process impurities are not merely a potency or aesthetic concern measured as a decimal — they can be an immunological variable. That reframes why impurity profiling, not just a headline purity number, belongs on a credible certificate.

• Lot-specific identity by mass spectrometry, matched to the declared sequence and salt form.
• Purity by a disclosed chromatographic method, with wavelength and whether RRF corrections were applied.
• An explicit impurity profile rather than only a single purity figure.
• Bacterial endotoxin per USP 85 against a stated limit.
• Counter-ion, net peptide content and water content for mass-balance interpretation.
• Traceability: the certificate references the exact lot, not a generic product specification.

The defensible, source-robust conclusion is qualitative: a supplier purity claim is a claim, measured identity and purity are evidence, and endotoxin and impurity profile are distinct attributes a purity percentage does not capture. Independent, lot-level verification exists precisely because these gaps are common and not visible from a label.